Searched for
US ALBUTEROL MARKET
Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...30 Oct, 2025, 01.41 PM IST- Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy'sCipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...26 Oct, 2023, 04.36 PM IST
- US unit of India's Cipla recalls six batches of bronchospasm inhalerIndian pharmaceutical company Cipla has recalled six batches of its Albuterol Sulfate HFA Inhalation Aerosol in the US due to a container d...07 Jul, 2023, 10.36 AM IST
- Market movers: Monday mayhem eludes Sharda Cropchem, Cipla sharesSharda stock jumped after the company on Friday reported a two-fold jump in consolidated net profits24 Jan, 2022, 06.37 PM IST
- Buy Lupin, target price Rs 1150: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 42717.22 Crore) operating in Pharmaceuticals s...12 Jan, 2022, 11.33 AM IST
- Cipla confident about earning trajectory over next couple of quarters: Umang Vohra“We feel confident about the margin profile of the company and we are hoping to maintain that in the quarters going forward.”.09 Aug, 2021, 02.38 PM IST
- Zydus Cadila gets USFDA nod for generic drugAlbuterol is a bronchodilator which helps open up the airways in the lungs to make it easier to breathe. The medicine is used to treat and ...23 Oct, 2020, 01.04 PM IST
- Cipla, Lupin may gain from Perrigo's drug recall, says MacquariePerrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to cloggin...18 Sep, 2020, 03.22 PM IST
- Licence to sell cancer drug biggest opportunity for Dr Reddy’s in US market: Nirmal Bang‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’18 Sep, 2020, 11.44 AM IST
- Lupin gets US health regulator's approval for asthmatic symptoms prevention drugThe approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin sai...25 Aug, 2020, 10.45 AM IST
- Cipla Q1 results preview: Profit to tank 30-50%, sharp margins fall likelyNirmal Bang expects the company to report a 45 per cent decline in net profit at Rs 262.80 crore on a 0.8 per cent fall in net sales at Rs ...07 Aug, 2020, 12.51 PM IST
- Stock Ideas: Motilal has a buy call on Lupin, target price Rs 1,000The brokerage expects 40 per cent earnings CAGR over FY20-22E, led by niche launches.01 Jun, 2020, 12.09 PM IST
- A big opportunity is beginning to unlock for us in the US: Cipla'Inhaler opportunity can add to Cipla’s position in lung medicines.'18 May, 2020, 03.41 PM IST
- Buy Cipla, target price Rs 668: ICICI SecuritiesThe brokerage has raised FY21-FY22 EPS estimates by 11-12 per cent on generic Proventil approval and the increase in Rs/$ rate to 74 from 7...13 Apr, 2020, 12.08 PM IST
- Buy Cipla, target price Rs 522: Emkay GlobalCipla has received approval for generic proventil MDI (Albuterol Sulphate 90mcg/inhalation). This can lead to 3-4 per cent EPS accretion to...13 Apr, 2020, 09.55 AM IST
- Cipla hits 15% upper circuit as USFDA gives final approval to Albuterol Inhalation AerosolFollowing the development, the scrip hit its 15 per cent upper circuit limit at Rs 589.95.09 Apr, 2020, 03.47 PM IST
- Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation AerosolIn a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...09 Apr, 2020, 01.14 PM IST
Load More
